Thtx may get a mention at Cantor Nash KOL callThe analyst overthere that still has hold on to your seat a 12 month 9usd target on Th.. she covers Pfizer too and is considered pretty respectable it seems. That being said the Cantor reports states the following: Potential for Theratechnologies in NASH as well as HIV.. Institutional clients only...Madrigal will be there too. Thera is not officially prensenting I've been told but they may be mentioned as a potential Nash player that spent like 100M+ on it's P3 program and that is woth 78M now if you count the paper clips and the erasers overthere. If it looks to good to be true most of the time it is...